Psychedelic Alpha

Welcome to our fourth Field Note. As a reminder, Field Notes are timely, candid voice notes from our Founder and Editor, Josh Hardman, that give our Pα+ readers a pulse on recent developments in psychedelic drug development, policy, and access. In this Field Note, Josh shares stories from another busy month in the field, including…

The U.S. Health Resources and Services Administration (HRSA) has received 59 comments in response to its request for information (RFI) regarding ‘training and care delivery models for safe administration of potential FDA-approved psychedelic therapies in ambulatory settings.’ HRSA, which is housed in the Department of Health and Human Services is, in some respects, a lesser-k...

Dr. Husseini Manji’s affiliations are quite the laundry list: a professor of psychiatry at the University of Oxford with adjunct and visiting positions at Yale and Duke, as well as serving as co-chair of the UK government’s mental health mission. But it’s his earlier work as a pioneer in the development of rapid-acting antidepressants that concerns this interview, with Manji’...